Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
The APDN news archive on Stock Titan covers the historical disclosures and announcements of Applied DNA Sciences, Inc., a biotechnology company that developed and commercialized polymerase chain reaction (PCR)-based technologies for DNA production and detection and later adopted a BNB-focused digital asset treasury strategy. During the period when it traded under the Nasdaq symbol APDN, the company issued news on operational restructuring, platform development, customer activity, and capital markets transactions.
Readers can review company updates describing the transition to a pure play provider of synthetic DNA and mRNA manufacturing solutions through its majority-owned subsidiary LineaRx, Inc., including the focus on its LineaDNA, LineaRNAP, and LineaIVT platforms. News items detail workforce reductions, the exit from DNA tagging and security products and services, the closure of Applied DNA Clinical Labs, and the consolidation of operations behind LineaRx to support advanced biotherapeutics and diagnostic applications.
The archive also includes announcements related to conference participation and scientific posters showcasing the LineaDNA and LineaIVT platforms, follow-on orders for LineaDNA from a global in vitro diagnostics manufacturer for use in a cancer diagnostic application, and engagements with mRNA-focused contract development and manufacturing organizations. Financial news covers quarterly results, non-GAAP metrics such as Adjusted EBITDA and monthly net cash burn, and commentary on cost optimization and capital allocation.
Later APDN news releases document the company’s initiation of a BNB-focused digital asset treasury strategy, private placement commitments to fund BNB acquisitions, and the planned change of its Nasdaq ticker from APDN to BNBX to reflect this strategic focus. These items describe agreements with Cypress LLC and Cypress Management LLC for digital asset management and advisory services, as well as the involvement of institutional and crypto-native investors. By following this archive, investors can trace how APDN evolved from a biotechnology-focused issuer into BNB Plus Corp. (BNBX) with a combined profile in nucleic acid production and digital asset treasury management.
Applied DNA Sciences, Inc. (NASDAQ: APDN) will release its fiscal 2020 fourth quarter financial results on December 17, 2020, after market close. A conference call is scheduled for 4:30 p.m. EST, with a live broadcast available online. The company provides solutions for supply chain security, anti-counterfeiting, and therapeutic drug candidates. Investors can access a recording of the call and subsequent webcasts on the company's website.
Applied DNA Sciences (NASDAQ: APDN) announced the expansion of its commercial activities through a multi-year Master Services Agreement with Nutrition21. Nutrition21 will utilize Applied DNA's CertainT® platform to secure its dietary supplement ingredients’ intellectual property. The agreement includes follow-on orders for the second year of commercial production, with shipments expected in the current fiscal quarter. Nutrition21 is the first to adopt this platform, which will enhance ingredient authenticity and address IP infringement, supporting both companies’ growth in the dietary supplements market.
Applied DNA Sciences (NASDAQ: APDN) announced its subsidiary, Applied DNA Clinical Laboratories, will implement its COVID-19 surveillance testing program, safeCircle™, for Stony Brook University’s basketball teams. This program will facilitate three testing sessions weekly, using the Linea™ COVID-19 Assay Kit, enhancing safety for athletes and staff.
Dr. James A. Hayward highlighted the significance of this partnership, aiming to set a testing model for other sports teams. The initiative represents a strategic expansion of ADCL's surveillance testing services amid ongoing COVID-19 challenges.
Applied DNA Sciences (NASDAQ: APDN) has received approvals from New York and U.S. agricultural departments for a veterinary trial of its LinearDNA COVID-19 vaccine candidate, aimed at domestic felines. This redesigned trial allows faster data collection and aims for a USDA APHIS conditional license for commercial sales after demonstrating safety and immunogenicity. The trial, beginning within 90 days, will recruit a smaller group of healthy felines to assess the vaccine’s effectiveness, responding to serious COVID-19 risks in animal reservoirs and potential spillover effects on human populations.
Applied DNA Sciences, Inc. (NASDAQ: APDN) will participate virtually in the Imperial Capital 2020 Security Investor Conference on December 3, 2020. CEO Dr. James A. Hayward is scheduled to present at 10:45 a.m. EST and will hold one-on-one meetings throughout the day. A webcast of the presentation will be archived within 24 hours on the company's Investor Relations page. Applied DNA specializes in PCR-based DNA manufacturing, focusing on supply chain security and anti-counterfeiting solutions.
Applied DNA Sciences (NASDAQ:APDN) announced that the FDA has granted an Emergency Use Authorization (EUA) amendment for its Linea™ COVID-19 Assay Kit. This amendment allows the assay kit to operate on the Applied Biosystems™ 7500 Fast Dx system, expanding testing capacity to 400-800 tests per 24 hours in clinical labs. CEO Dr. James A. Hayward emphasized this will facilitate broader adoption of their test. Additionally, Applied DNA noted ongoing efforts in enhancing its safeCircle™ pooled testing platform while addressing deficiencies identified in its clinical lab certification process.
Applied DNA Sciences (NASDAQ: APDN) has secured a blanket purchase order for its Linea™ COVID-19 Assay Kit from an existing customer, facilitating 10,000 tests. The company has already shipped part of this order in the current fiscal quarter, with further deliveries anticipated. The assay kit received Emergency Use Authorization (EUA) from the FDA in May 2020, allowing its use for SARS-CoV-2 detection. Additionally, Applied DNA has applied for an amendment to extend its EUA to include a widely used PCR system.
Applied DNA Sciences (NASDAQ: APDN) has been selected by Stony Brook University Hospital to provide its Linea™ COVID-19 Assay Kit for a new COVID-19 surveillance testing program. This program aims to monitor COVID-19 cases among 9,000 faculty and staff, utilizing pooled testing to allow for early detection. The initial order includes 3,400 tests, with potential for recurring orders. The Company anticipates significant sales opportunities through this partnership and plans to expand its testing capacity through its safeCircle™ platform, offering rapid results.
Applied DNA Sciences (NASDAQ: APDN) is enhancing its COVID-19 testing capacity through its subsidiary, Applied DNA Clinical Laboratories, in response to a surge in cases. The company aims to expand its surveillance testing program, known as safeCircle, which utilizes pooled testing to quickly identify infections. The expansion includes increased robotic automation to boost testing throughput and additional PCR instruments. Recent successes demonstrate the program's effectiveness in early infection detection, with plans for further regional market growth.
Applied DNA Sciences (NASDAQ: APDN) has announced contracts for COVID-19 surveillance testing anticipated to generate over $1 million in annual revenue starting October 1, 2020. The contracts involve private schools and small enterprises in New York. The company is also advancing its LineaTM COVID-19 Diagnostic Assay Kit sales strategy. Additionally, it is progressing towards CLEP-CLIA certification to legally conduct clinical lab testing. Successful certification could broaden testing capabilities and revenue potential.